
Bruno Ségui
69
Documents
Publications
Publications
Anti-TNF in melanoma immunotherapy: from basic research to early clinical trials in advanced melanoma patientsSummer school on Medicines, Vitor Faça, Jun 2024, Ribeirão Preto, Brazil
Communication dans un congrès
hal-04991577
v1
|
|
Targeting ceramide metabolism in melanoma to improve the efficacy of immune checkpoint inhibitor therapy: from basic mechanisms to the clinic.XV SPHINGOLIPID CLUB MEETING, Sep 2024, Erlangen-Nürnberg, Germany
Communication dans un congrès
hal-04974692
v1
|
|
Anti-TNF in melanoma therapy: from basic research to early clinical trials in advanced melanoma patients.Summer School on Medicines, Marçal Pastor-Anglada, Jul 2023, Barcelona (ES), Spain
Communication dans un congrès
hal-04991531
v1
|
|
Triple combination of anti-CTLA-4, anti-PD-1 and anti-TNF in mouse melanoma models and advanced melanoma patients.EACR conferences “Defence is the Best Attack: Immuno-Oncology Breakthroughs”, Joan Seoane, May 2023, Barcelona, Spain
Communication dans un congrès
hal-04974544
v1
|
|
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation.International Ceramide Conference, Apr 2023, Charleston, South Carolina, United States
Communication dans un congrès
hal-04974508
v1
|
|
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation: from basic research to immunotherapy in advanced melanoma patients.FEBS Sphingolipid biology, Oct 2023, Funchal (Madeira Island), Portugal
Communication dans un congrès
hal-04974669
v1
|
|
Anti-TNF in melanoma immunotherapy: from basic findings to the clinic.10èmes Journée d’Immunologie et Immunothérapie des Cancers (JIIC), Ali Bettaieb, Dec 2022, Dijon, France
Communication dans un congrès
hal-04974429
v1
|
|
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients.ESMED general assembly, Aug 2022, Madrid (Online Only), Spain
Communication dans un congrès
hal-04974455
v1
|
|
Early phase clinical trial in melanoma: a repositioning ventureThe 12th Summer School on Medicines, Pierre Cordelier, Jul 2022, Toulouse, France
Communication dans un congrès
hal-04975301
v1
|
|
Anti-TNF in melanoma immunotherapy: from basic findings to the clinicMelanoma Workshop 2021, C. BERTOLOTTO and R. BALLOTTI, Aug 2021, Nice, France
Communication dans un congrès
hal-04974420
v1
|
|
Anti-TNF + Nivolumab + Ipilimumab pour le traitement du mélanome avancé : premiers résultats de l’essai clinique TICIMELJournées dermatologiques de Paris, Nov 2021, Paris, France
Communication dans un congrès
hal-04970832
v1
|
|
Combining TNF inhibitors to anti-PD-1 and anti-CTLA-4 for the treatment of advanced melanoma patients17ème journées du Cancéropôle Grand Sud-Ouest, Nov 2021, Carcassone, France
Communication dans un congrès
hal-04970934
v1
|
|
Neutral sphingomyelinase 2 heightens anti-melanoma immune responses and anti-PD-1 therapy efficacy.The 141st Annual Meeting of the Pharmaceutical Society of Japan, Pharmaceutical Society of Japan, Mar 2021, Hiroshima (Virtual meeting), Japan
Communication dans un congrès
hal-04974402
v1
|
|
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with anti-PD-1.Toulouse Oncoweek, Feb 2020, Toulouse, France
Communication dans un congrès
hal-04971026
v1
|
|
Ceramide metabolism in melanoma: From basic mechanisms to Immunotherapy in advanced melanoma patients.Introduction lecture at the 14th Sphingo Therapy Conference, Toshiro Okazaki, Jan 2020, Kanazawa, Japan
Communication dans un congrès
hal-04974371
v1
|
|
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients.FEBS 2019 Sphingolipid Biology: Sphingolipids in Physiology and Pathology, Giovanni D'Angelo, Christopher J. Clarke, Liana C. Silva, May 2019, Cascais, Portugal
Communication dans un congrès
hal-04974329
v1
|
|
TNF-dependent mechanisms of immune escape and resistance to immunotherapy3rd European R&D Day in immuno-oncology, Mar 2019, Amsterdam, Netherlands
Communication dans un congrès
hal-04974781
v1
|
|
Targeting TNF-alpha to overcome resistance to immunotherapy in melanoma11th Summer School on Medicines, Denis Deblois, Jun 2019, Montreal, Canada
Communication dans un congrès
hal-04974731
v1
|
|
Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1Canceropole GSO, Canceropole GSO, Nov 2019, Arcachon, France
Communication dans un congrès
hal-04993281
v1
|
|
Anti-TNF in melanoma immunotherapy: from basic findings to the clinic9ème Journée d’Immunologie et Immunothérapie des Cancers (JIIC), Dec 2019, Dijon, France
Communication dans un congrès
hal-04974761
v1
|
|
Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanomaToulouse Oncoweek, Feb 2018, Toulouse, France
Communication dans un congrès
hal-04970883
v1
|
Impact of TNF on ceramide metabolism and on the inflammatory and differentiation state of melanoma: from basic mechanisms to the clinic.Life Sciences [q-bio]. Université Toulouse 3 (Paul Sabatier ), 2023. English. ⟨NNT : 2023TOU30348⟩
Thèse
tel-05002536
v1
|
|
|
Rôle du métabolisme du céramide dans la dédifférenciation du mélanome induite par le TNFBiologie cellulaire. Université toulouse 3 Paul Sabatier, 2022. Français. ⟨NNT : ⟩
Thèse
tel-04967074
v1
|
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer.France, Patent n° : WO2024052356A1. 2022
Brevet
inserm-04976432
v1
|
|
Use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer.France, Patent n° : WO2020208060A1. 2020
Brevet
inserm-04976354
v1
|
|
Methods for predicting the survival of patients suffering from melanoma.France, Patent n° : WO2020193746A1. 2019
Brevet
inserm-04976387
v1
|
|
Use of sk1 as biomarker for predicting response to immune checkpoint inhibitors.France, Patent n° : WO2019162325A1. 2019
Brevet
inserm-04976375
v1
|
Chargement...
Chargement...